KR20230011910A - 신장 손상을 치료하기 위한 조성물 및 방법 - Google Patents
신장 손상을 치료하기 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20230011910A KR20230011910A KR1020227032520A KR20227032520A KR20230011910A KR 20230011910 A KR20230011910 A KR 20230011910A KR 1020227032520 A KR1020227032520 A KR 1020227032520A KR 20227032520 A KR20227032520 A KR 20227032520A KR 20230011910 A KR20230011910 A KR 20230011910A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- renal
- alkylene
- kidney
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979813P | 2020-02-21 | 2020-02-21 | |
| US62/979813 | 2020-02-21 | ||
| PCT/US2021/019084 WO2021168430A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods for treating renal injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230011910A true KR20230011910A (ko) | 2023-01-25 |
Family
ID=77391654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227032520A Withdrawn KR20230011910A (ko) | 2020-02-21 | 2021-02-22 | 신장 손상을 치료하기 위한 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12616681B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4106748A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023515081A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230011910A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021224268A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168728A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010258A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021168430A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| WO2020106998A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| AU2021224268A1 (en) | 2020-02-21 | 2022-09-15 | Case Western Reserve University | Compositions and methods for treating renal injury |
| WO2024099429A1 (zh) * | 2022-11-11 | 2024-05-16 | 赛诺哈勃药业(成都)有限公司 | 一种调控15-pgdh活性的化合物及其制备方法 |
Family Cites Families (214)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3382248A (en) | 1965-11-01 | 1968-05-07 | Upjohn Co | 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines |
| FR2274951A1 (fr) | 1974-06-11 | 1976-01-09 | Ciba Geigy Ag | Procede de preparation d'images polymeres stables par photopolymerisation dans une matrice |
| GR80916B (en) | 1983-11-14 | 1985-03-12 | Dow Chemical Co | Method of preparing 1,2,4-triazolo (1,5-a)-pyrimidine-2-sulfonyl chlorides |
| SE8405924L (sv) | 1984-11-23 | 1986-05-24 | Pharmacia Ab | Nya azoforeningar |
| EP0271273A3 (en) | 1986-12-08 | 1989-07-12 | Merck & Co. Inc. | Thieno-and furopyridine sulfonamides |
| US4904672A (en) | 1987-01-30 | 1990-02-27 | Merck & Co., Inc. | Derivatives of 3-hydroxyazabenzo[b]thiophene useful as 5-lipoxygenase inhibitors |
| GB8709248D0 (en) | 1987-04-16 | 1987-05-20 | Wyeth John & Brother Ltd | Azo compounds |
| US4910226A (en) | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| LU87308A1 (fr) | 1988-08-01 | 1990-03-13 | Oreal | Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux |
| WO1990006100A1 (en) | 1988-12-02 | 1990-06-14 | The Upjohn Company | Minoxidil and vasoconstrictor compositions for treating alopecia |
| EP0378508B1 (de) | 1989-01-11 | 1995-03-01 | Ciba-Geigy Ag | Antidots zur Verbesserung der Kulturpflanzenvertäglichkeit agrochemischer Wirkstoffe |
| US5015629A (en) | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
| FR2651122B1 (fr) | 1989-08-29 | 1994-10-28 | Oreal | Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3. |
| US5480913A (en) | 1989-09-27 | 1996-01-02 | Arch Development Corporation | Anti-androgen compounds |
| EP0434624B1 (de) | 1989-12-22 | 1995-02-08 | Ciba-Geigy Ag | Triazolylsulfonamide |
| US5217521A (en) | 1989-12-22 | 1993-06-08 | Ciba-Geigy Corporation | Triazolylsulfonamides |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| FR2662607B1 (fr) | 1990-05-30 | 1992-08-28 | Oreal | Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 . |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2677884B1 (fr) | 1991-06-20 | 1993-07-09 | Oreal | Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues. |
| FR2678929A1 (fr) | 1991-07-11 | 1993-01-15 | Oreal | Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde. |
| FR2683531B1 (fr) | 1991-11-13 | 1993-12-31 | Rhone Poulenc Rorer Sa | Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1993013664A2 (en) | 1992-01-11 | 1993-07-22 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| CA2142300C (en) | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| US5445164A (en) | 1993-05-11 | 1995-08-29 | Gynetech, Inc. | Cervical tissue sampling device |
| WO1995005843A1 (en) | 1993-08-25 | 1995-03-02 | Systemix, Inc. | Method for producing a highly enriched population of hematopoietic stem cells |
| TW369521B (en) | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| FR2711060B1 (fr) | 1993-10-13 | 1995-11-17 | Oreal | Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet. |
| SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
| US5405842A (en) | 1994-01-28 | 1995-04-11 | Silverman; Bernard A. | Treatment of steroid dependent asthmatics |
| FR2719481B1 (fr) | 1994-05-05 | 1996-05-31 | Oreal | Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux. |
| US5516779A (en) | 1994-06-08 | 1996-05-14 | Merck & Co., Inc. | 17β-substituted-6-azasteroid derivatives useful as 5α-reductase inhibitors |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5807895A (en) | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
| US5529769A (en) | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
| FR2732597B1 (fr) | 1995-04-05 | 1997-05-16 | Oreal | Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6 |
| US5631282A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | Triterpenes |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| FR2739553B1 (fr) | 1995-10-06 | 1998-01-02 | Oreal | Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute |
| EP0918518A4 (en) | 1996-04-19 | 2002-05-02 | Univ California | TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS. |
| JP3049593B2 (ja) | 1996-05-01 | 2000-06-05 | 株式会社ビメーク | 育毛・養毛剤 |
| US6281227B1 (en) | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| DE69823852T2 (de) | 1997-02-04 | 2005-05-19 | Johnstone, Murray A., Seattle | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
| JP3217293B2 (ja) | 1997-04-17 | 2001-10-09 | 株式会社アールテック・ウエノ | 発毛・育毛剤 |
| CA2295595A1 (en) | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| ATE268782T1 (de) | 1997-12-12 | 2004-06-15 | Univ Southern California | Zusammensetzungen zur wundheilung |
| US6214533B1 (en) | 1998-04-10 | 2001-04-10 | Konica Corporation | Thermally developable photosensitive material |
| US20040241726A1 (en) | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
| US20040241727A1 (en) | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of schizophrenia related gene transcripts in blood |
| US7473528B2 (en) | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
| US8068897B1 (en) | 1999-03-01 | 2011-11-29 | Gazdzinski Robert F | Endoscopic smart probe and method |
| EP1080728A1 (en) | 1999-03-16 | 2001-03-07 | Toray Industries, Inc. | Prostaglandin ep4 receptor agonist and treatment method |
| AU7360700A (en) | 1999-09-09 | 2001-04-10 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
| US20020146439A1 (en) | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| WO2001072268A1 (en) | 2000-03-31 | 2001-10-04 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| FR2812190B1 (fr) | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| FR2812191B1 (fr) | 2000-07-28 | 2003-10-17 | Oreal | Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques |
| GEP20053675B (en) | 2001-03-30 | 2005-11-25 | Pfizer Prod Inc | Pyridazinone Aldose Reductase Inhibitors |
| US7004913B1 (en) | 2001-05-04 | 2006-02-28 | Cdx Laboratories, Inc. | Retractable brush for use with endoscope for brush biopsy |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| US20030096823A1 (en) | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
| JP2003286171A (ja) | 2002-03-28 | 2003-10-07 | Sumitomo Pharmaceut Co Ltd | Par阻害剤 |
| FR2838641B1 (fr) | 2002-04-23 | 2005-12-23 | Oreal | Composition cosmetique, procede de traitement cosmetique et preparation d'une composition pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux |
| US7320967B2 (en) | 2002-04-23 | 2008-01-22 | L'oreal | Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair |
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| JP2004067629A (ja) | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
| US20060051540A1 (en) | 2002-09-20 | 2006-03-09 | Seiji Kagawa | Shape-memory polybutylene terephthalate film, production process and use thereof, and process for production of polybutylene terephthalate film |
| FR2845000B1 (fr) | 2002-09-27 | 2005-05-27 | Oreal | Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute |
| JP2006505559A (ja) | 2002-10-18 | 2006-02-16 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール |
| FR2845917B1 (fr) | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
| US7105117B2 (en) | 2003-01-06 | 2006-09-12 | General Motors Corporation | Manufacturing method for increasing thermal and electrical conductivities of polymers |
| WO2004069213A2 (en) | 2003-01-15 | 2004-08-19 | L'oreal | Cosmetic composition comprising a 2-alkylideneaminooxyacetamide |
| EP1594438B1 (fr) | 2003-02-12 | 2013-07-17 | L'Oréal | Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères |
| WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| DE602004027171D1 (de) | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| CN1589793A (zh) | 2003-07-24 | 2005-03-09 | 山东绿叶天然药物研究开发有限公司 | 鞣酸小檗碱在制备治疗溃疡性结肠炎药物中的应用 |
| ES2559779T3 (es) | 2003-08-29 | 2016-02-15 | Vernalis (R&D) Limited | Compuestos de pirimidotiofeno |
| US20050187221A1 (en) | 2003-09-08 | 2005-08-25 | Japan Tobacco Inc. | Method of treating ischemia reperfusion injury |
| CN1898563B (zh) | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | 诊断乳腺癌的方法 |
| WO2005030773A1 (ja) | 2003-09-26 | 2005-04-07 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピラゾロピリミジン誘導体 |
| FR2860431A1 (fr) | 2003-10-02 | 2005-04-08 | Oreal | Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute |
| US20050209181A1 (en) | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
| CA2551792A1 (en) | 2003-12-31 | 2005-07-21 | Basell Poliolefine Italia S.R.L. | Filled olefin polymer compositions having improved mechanical properties and scratch resistance |
| EP1725544B1 (en) | 2004-03-09 | 2009-05-27 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| JP2005325099A (ja) | 2004-04-12 | 2005-11-24 | Sankyo Co Ltd | チエノピリジン誘導体 |
| TW200609237A (en) | 2004-04-12 | 2006-03-16 | Sankyo Co | Thienopyridine derivatives |
| EP1781289A1 (en) | 2004-07-22 | 2007-05-09 | PTC Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| WO2006048266A2 (en) | 2004-11-04 | 2006-05-11 | Roche Diagnostics Gmbh | Gene expression profiling of leukemias with mll gene rearrangements |
| WO2006048264A2 (en) | 2004-11-04 | 2006-05-11 | Roche Diagnostics Gmbh | Gene expression profiling in acute lymphoblastic leukemia (all), biphenotypic acute leukemia (bal), and acute myeloid leukemia (aml) m0 |
| US20070155884A1 (en) | 2004-11-12 | 2007-07-05 | Basell Poliolefine Italia S.R.L. | Filled olefin polymer compositions having improved mechanical properties and scratch resistance |
| US8000795B2 (en) | 2004-12-17 | 2011-08-16 | Lozano Andres M | Cognitive function within a human brain |
| MX2007008227A (es) | 2005-01-05 | 2007-09-11 | Novacea Inc | Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos. |
| AU2006206573B9 (en) | 2005-01-19 | 2011-09-29 | Merck Sharp & Dohme Corp. | Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US20080254459A1 (en) | 2005-03-05 | 2008-10-16 | (Harc) Houston Advanced Research Center | Methods and Biomarkers for Detecting Nanoparticle Exposure |
| EP1871776A2 (en) | 2005-03-09 | 2008-01-02 | Schering Corporation | Fused thieno[2,3-b]pyridine and thiazolo[5,4-b]pyridine compounds for inhibiting ksp kinesin activity |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| US20090118337A1 (en) | 2005-06-03 | 2009-05-07 | Davis Pamela B | Methods and compositions for treating inflammation |
| AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070071699A1 (en) | 2005-06-28 | 2007-03-29 | L'oreal | Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening |
| US20070059265A1 (en) | 2005-06-28 | 2007-03-15 | L'oreal | Benzylidene-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss and/or for increasing the density of keratin fibers |
| EP2305811A1 (en) | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| WO2007019180A2 (en) | 2005-08-04 | 2007-02-15 | Science & Technology Corporation @ Unm | Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| AU2006284751A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| AR056200A1 (es) | 2005-09-27 | 2007-09-26 | Wyeth Corp | Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa |
| US20070078175A1 (en) | 2005-10-05 | 2007-04-05 | L'oreal | Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof |
| DE602006016643D1 (de) | 2005-12-20 | 2010-10-14 | Richter Gedeon Nyrt | THIENOÄ2,3-bÜPYRIDIN DERIVATE |
| WO2007101225A2 (en) | 2006-02-27 | 2007-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to identify inhibitors of the unfolded protein response |
| WO2007100775A2 (en) | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| AU2007243466B2 (en) | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| KR20090125246A (ko) | 2007-03-09 | 2009-12-04 | 코와 가부시키가이샤 | 전신성 에리테마토데스의 예방 및/또는 치료제 |
| US8153798B2 (en) | 2007-03-09 | 2012-04-10 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
| AR060498A1 (es) | 2007-04-17 | 2008-06-18 | Richter Gedeon Vegyeszet | Compuestos de tieno [2,3-b] piridinas |
| PE20090365A1 (es) | 2007-06-14 | 2009-04-04 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| KR100901127B1 (ko) | 2007-06-22 | 2009-06-08 | 한국과학기술연구원 | 독소루비신 처리에 따른, 심장독성 유발 약물 검색용마커유전자 및 이를 이용한 심장독성 유발 약물 검색 방법 |
| BRPI0813556A2 (pt) | 2007-07-10 | 2015-06-16 | Univ Columbia | Termoestabilização de proteínas |
| US8981060B2 (en) | 2007-08-27 | 2015-03-17 | Novelmed Therapuetics, Inc. | Method of inhibiting complement activation with factor Bb specific antibodies |
| FR2920309B1 (fr) | 2007-08-28 | 2010-05-28 | Galderma Res & Dev | Utilisation de travoprost pour traiter la chute des cheveux |
| DE102007049451A1 (de) | 2007-10-16 | 2009-04-23 | Merck Patent Gmbh | 5-Cyano-thienopyridine |
| WO2009073460A2 (en) | 2007-12-03 | 2009-06-11 | Bausch & Lomb Incorporated | Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection |
| WO2009082691A1 (en) | 2007-12-21 | 2009-07-02 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2011512346A (ja) | 2008-02-15 | 2011-04-21 | ノボビオン オイ | クルクミンの可溶性錯体 |
| CA2753844A1 (en) | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| WO2009120877A2 (en) | 2008-03-26 | 2009-10-01 | The Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| US7629112B1 (en) | 2008-05-30 | 2009-12-08 | Eastman Kodak Company | Color photographic materials with yellow minimum density colorants |
| JP5180882B2 (ja) | 2008-07-29 | 2013-04-10 | 株式会社プライムポリマー | ポリプロピレン樹脂組成物、およびその成形体 |
| BRPI0918971A2 (pt) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| US20100093764A1 (en) | 2008-10-13 | 2010-04-15 | Devraj Chakravarty | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| EP2383263B1 (en) | 2008-12-30 | 2014-04-16 | Industry-academic Cooperation Foundation, Chosun University | Novel thiazolidinedione derivative and use thereof |
| PT2385832E (pt) | 2009-01-08 | 2015-11-02 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| US8957064B2 (en) | 2009-02-13 | 2015-02-17 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| US20100248365A1 (en) | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
| KR20100137090A (ko) | 2009-06-22 | 2010-12-30 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| WO2011006100A1 (en) | 2009-07-09 | 2011-01-13 | Crescendo Therapeutics, Llc | Method of wound healing and scar modulation |
| CA2775354C (en) | 2009-09-29 | 2019-01-15 | Margaret Phillips | Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| EP2308883A1 (en) | 2009-10-05 | 2011-04-13 | Centre National De La Recherche Scientifique | New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria |
| WO2011094847A1 (en) | 2010-02-04 | 2011-08-11 | Penn Linda Z | Methods and compositions for diagnosing and treating patients having multiple myeloma that respond to statin therapy |
| US10231976B2 (en) | 2010-02-08 | 2019-03-19 | Prairie Pharmaceuticals LLC | Methods for the use of progestogen as a glucocorticoid sensitizer |
| GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| KR101684671B1 (ko) | 2010-09-08 | 2016-12-09 | (주)아모레퍼시픽 | 신규한 자외선 흡수제용 퀴녹살린계 화합물 |
| US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| AU2012208283B2 (en) * | 2011-01-20 | 2017-01-05 | Oneday - Biotech And Pharma Ltd. | Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof |
| GB201107197D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Compounds |
| JP6051632B2 (ja) | 2011-07-20 | 2016-12-27 | 日立化成株式会社 | 研磨剤及び基板の研磨方法 |
| GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
| US20130078632A1 (en) | 2011-09-23 | 2013-03-28 | Academisch Medisch Centrum | Materials and methods for prognosis of progression of barrett's esophagus |
| CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
| GB201120993D0 (en) | 2011-12-06 | 2012-01-18 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2013088853A1 (ja) | 2011-12-15 | 2013-06-20 | 国立大学法人東京農工大学 | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター |
| EP2806876A4 (en) | 2012-01-25 | 2016-03-02 | Proteostasis Therapeutics Inc | Proteasome activity enhancing compounds |
| KR101370670B1 (ko) | 2012-03-12 | 2014-03-06 | 조선대학교산학협력단 | 플라본 화합물의 15-하이드록시프로스타글란딘 탈수소효소 활성의 억제 효능 및 그의 용도 |
| CA2870666A1 (en) | 2012-04-16 | 2013-10-24 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| WO2016144958A1 (en) * | 2015-03-08 | 2016-09-15 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating fibrosis |
| KR101244964B1 (ko) | 2012-05-30 | 2013-03-18 | 조선대학교산학협력단 | 15-히드록시프로스타글란딘 디히드로게나제 및 pge2 활성을 조절하는 황칠나무 추출물의 용도 |
| US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
| WO2014081878A2 (en) | 2012-11-21 | 2014-05-30 | Stategics, Inc. | Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival |
| CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| WO2014160947A1 (en) | 2013-03-29 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof |
| US20160376430A1 (en) | 2013-07-08 | 2016-12-29 | Prime Polymer Co., Ltd. | Propylene resin composition |
| HK1223096A1 (zh) | 2013-09-25 | 2017-07-21 | Vertex Pharmaceuticals Incorporated | 用作par-2信號通路抑制劑的咪唑並噠嗪 |
| CA2927730A1 (en) | 2013-10-15 | 2015-05-07 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2015077382A2 (en) | 2013-11-19 | 2015-05-28 | Fight Against Cancer Innovation Trust | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma |
| CN106458934B (zh) | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
| EP3179995B1 (en) | 2014-08-12 | 2018-11-07 | University of Pécs (Pécsi Tudományegyetem) | Methods and materials for reducing ischemia-reperfusion injury |
| KR102255308B1 (ko) | 2014-11-18 | 2021-05-24 | 삼성전자주식회사 | 아세틸살리실산을 포함하는 개체의 스테로이드 부작용을 예방 또는 치료하기 위한 조성물 및 그의 용도 |
| EP3237639A2 (en) | 2014-12-23 | 2017-11-01 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| WO2016164770A1 (en) | 2015-04-10 | 2016-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of dim-related indoles |
| EP3283074A4 (en) | 2015-04-14 | 2018-12-05 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| ES2733200T3 (es) | 2015-05-22 | 2019-11-28 | Borealis Ag | Composite de polipropileno - fibra de carbono |
| ES2733836T3 (es) | 2015-05-22 | 2019-12-03 | Borealis Ag | Composición polimérica reforzada con fibra |
| EP4538365A3 (en) | 2016-03-04 | 2025-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
| CA3031091A1 (en) | 2016-07-18 | 2018-01-25 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| KR20190086764A (ko) | 2016-11-30 | 2019-07-23 | 앵스티띠 파스퇴르 | 사람 선천성 림프 세포 전구체: 확인, 특성화, 적용 |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| JP7178360B2 (ja) | 2017-04-07 | 2022-11-25 | ケース ウエスタン リザーブ ユニバーシティ | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
| WO2018196870A1 (zh) | 2017-04-28 | 2018-11-01 | 中国医学科学院阜外医院 | 靶向前列腺素e2及其受体的药物与应用 |
| EP3630773A1 (en) | 2017-05-26 | 2020-04-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| GB2578539B (en) | 2017-06-09 | 2022-08-10 | Univ Leland Stanford Junior | Compositions and methods for preventing or treating muscle conditions |
| WO2019010482A1 (en) | 2017-07-07 | 2019-01-10 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR MODULATING COLUMN MATURATION |
| EP3781154A4 (en) | 2018-04-04 | 2022-02-23 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY INJURY |
| JP7349450B2 (ja) | 2018-04-25 | 2023-09-22 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規ヘテロアリール-トリアゾール化合物及びヘテロアリール-テトラゾール化合物 |
| GB201807968D0 (en) | 2018-05-16 | 2018-07-04 | Naturex Sa | Eutectic extract formation and purification |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| WO2020106998A1 (en) | 2018-11-21 | 2020-05-28 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
| WO2020160151A1 (en) | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| GB2599292A (en) | 2019-06-11 | 2022-03-30 | Univ Leland Stanford Junior | Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH) |
| JP7677983B2 (ja) | 2020-01-23 | 2025-05-15 | マイオフォルテ セラピューティクス,インク. | Pgdh阻害剤、およびその作製と使用の方法 |
| AU2021224268A1 (en) | 2020-02-21 | 2022-09-15 | Case Western Reserve University | Compositions and methods for treating renal injury |
| CR20220654A (es) | 2020-05-20 | 2023-08-24 | Rodeo Therapeutics Corp | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta |
| WO2021252936A1 (en) | 2020-06-11 | 2021-12-16 | The Board Of Trustees Of The Leland Stanford Junior University | Rejuvenation of aged tissues and organs by inhibition of the pge2 degrading enzyme, 15-pgdh |
| WO2022032230A1 (en) | 2020-08-07 | 2022-02-10 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration |
| US20240000758A1 (en) | 2020-10-23 | 2024-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh |
| JP2023552832A (ja) | 2020-12-09 | 2023-12-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 関節の構造および機能を改善するためのプロスタグランジン分解酵素15-pgdhの阻害法 |
-
2021
- 2021-02-22 AU AU2021224268A patent/AU2021224268A1/en active Pending
- 2021-02-22 CA CA3168728A patent/CA3168728A1/en active Pending
- 2021-02-22 EP EP21756279.2A patent/EP4106748A4/en not_active Withdrawn
- 2021-02-22 WO PCT/US2021/019084 patent/WO2021168430A1/en not_active Ceased
- 2021-02-22 MX MX2022010258A patent/MX2022010258A/es unknown
- 2021-02-22 JP JP2022549924A patent/JP2023515081A/ja active Pending
- 2021-02-22 KR KR1020227032520A patent/KR20230011910A/ko not_active Withdrawn
-
2022
- 2022-08-22 US US17/892,585 patent/US12616681B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230052363A1 (en) | 2023-02-16 |
| EP4106748A4 (en) | 2024-02-28 |
| CA3168728A1 (en) | 2021-08-26 |
| EP4106748A1 (en) | 2022-12-28 |
| US12616681B2 (en) | 2026-05-05 |
| WO2021168430A1 (en) | 2021-08-26 |
| AU2021224268A1 (en) | 2022-09-15 |
| MX2022010258A (es) | 2023-01-24 |
| JP2023515081A (ja) | 2023-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12616681B2 (en) | Compositions and methods for treating renal injury | |
| US20250325524A1 (en) | Compositions and methods for treating renal injury | |
| US20220096450A1 (en) | Compounds and Methods for Treating or Preventing Heart Failure | |
| JP2022521824A (ja) | アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用 | |
| ES2959419T3 (es) | Formulaciones secas por aspersión | |
| WO2020198712A1 (en) | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof | |
| US10730856B2 (en) | Benzimidazole derivatives as EP4 ligands | |
| JP2013518909A (ja) | アロステリックキナーゼ阻害が関係する治療方法および組成物 | |
| US20240279201A1 (en) | Dual wnt signaling pathway inhibitors and ampk activators for treatments of disease | |
| US11046657B2 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| US20190284183A1 (en) | Inhibition of bmp signaling, compounds, compositions and uses thereof | |
| JP2021515035A (ja) | HPTPβ阻害剤を使用して糖尿病性腎症を処置する方法 | |
| WO2002078705A1 (en) | Hsp inductor | |
| CN101478989A (zh) | 炎性肠病的处置剂 | |
| CN116096367A (zh) | Frs2–fgfr相互作用的小分子抑制剂及其在医学、在预防和治疗癌症中的用途 | |
| CA2813719A1 (en) | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
| TW201031659A (en) | Novel compound having 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-on structure and medicine containg same | |
| HK40052492A (en) | Compositions and methods for treating renal injury | |
| WO2014012000A2 (en) | No-releasing guanidine-coxib anti-cancer agents | |
| US20160340330A1 (en) | No-releasing nitrooxy-chromene conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P18-X000 | Priority claim added or amended |
St.27 status event code: A-2-2-P10-P18-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 St.27 status event code: A-3-3-R10-R13-asn-PN2301 |